1. Home
  2. CRUS vs COGT Comparison

CRUS vs COGT Comparison

Compare CRUS & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cirrus Logic Inc.

CRUS

Cirrus Logic Inc.

HOLD

Current Price

$122.79

Market Cap

5.9B

Sector

Technology

ML Signal

HOLD

Logo Cogent Biosciences Inc.

COGT

Cogent Biosciences Inc.

HOLD

Current Price

$40.99

Market Cap

6.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRUS
COGT
Founded
1984
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.9B
6.5B
IPO Year
1989
2018

Fundamental Metrics

Financial Performance
Metric
CRUS
COGT
Price
$122.79
$40.99
Analyst Decision
Strong Buy
Buy
Analyst Count
5
13
Target Price
$140.00
$28.08
AVG Volume (30 Days)
482.1K
3.1M
Earning Date
02-03-2026
11-03-2025
Dividend Yield
N/A
N/A
EPS Growth
19.23
N/A
EPS
7.02
N/A
Revenue
$1,948,426,000.00
N/A
Revenue This Year
$0.95
N/A
Revenue Next Year
$1.88
N/A
P/E Ratio
$17.44
N/A
Revenue Growth
2.19
N/A
52 Week Low
$75.83
$3.72
52 Week High
$136.92
$43.73

Technical Indicators

Market Signals
Indicator
CRUS
COGT
Relative Strength Index (RSI) 52.13 70.74
Support Level $121.94 $37.86
Resistance Level $126.97 $43.73
Average True Range (ATR) 2.82 2.08
MACD 0.60 -0.54
Stochastic Oscillator 65.03 54.50

Price Performance

Historical Comparison
CRUS
COGT

About CRUS Cirrus Logic Inc.

Cirrus Logic Inc is a provider of integrated circuits for audio and voice signal processing applications. The firm's products are organized into two streams: portable audio products, and HPMS Products. These products include aAmplifiers, codecs, smart codecs, analog-to-digital converters, digital-to-analog converters and standalone digital signal processors, Camera controllers, haptics and sensing solutions, and battery and power ICs. Roughly half of the firm's revenue is generated in China, with the rest coming from the United States, Europe, South Korea, and countries across the world.

About COGT Cogent Biosciences Inc.

Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.

Share on Social Networks: